ロード中...
Targeting MOR-mGluR(5) heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5
Pain is among the most common symptoms in cancer and approximately 90% of patients experience end-stage cancer pain. The management of cancer pain is challenging due to the significant side effects associated with opioids, and novel therapeutic approaches are needed. MMG22 is a bivalent ligand conta...
保存先:
| 出版年: | Neuropharmacology |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7210724/ https://ncbi.nlm.nih.gov/pubmed/31271770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2019.107690 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|